ArticleJournal of drug delivery2012
Cyclodextrin-containing polymers: versatile platforms of drug delivery materials.
Article in Journal of drug delivery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.Investigational new drugs · 2021Trial
- Positively Charged Polymers Based on Cyclodextrins for Trametinib and Selumetinib Delivery in Glioblastoma Cancer.ChemMedChem · 2026Article
- A ternary system of meloxicam with matching hydrophilic polymer and cyclodextrin for improved stability in liquid preprations.RSC advances · 2024Article
- A Systematic Review of Clinical Trials on the Efficacy and Safety of CRLX101 Cyclodextrin-Based Nanomedicine for Cancer Treatment.Pharmaceutics · 2023Review
- Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option.Molecular diagnosis & therapy · 2022Review
- β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
- Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects.Molecular therapy. Nucleic acids · 2021Article
- Exploring Charged Polymeric Cyclodextrins for Biomedical Applications.Molecules (Basel, Switzerland) · 2021Article
- Small interfering RNA for cancer treatment: overcoming hurdles in delivery.Acta pharmaceutica Sinica. B · 2020Review
- Fibrin Gels Entrapment of a Poly-Cyclodextrin Nanocarrier as a Doxorubicin Delivery System in an Orthotopic Model of Neuroblastoma: Evaluation of In Vitro Activity and In Vivo Toxicity.Pharmaceutical research · 2019Article
- Cyclodextrin polymers as nanocarriers for sorafenib.Investigational new drugs · 2018Article
- New doxorubicin nanocarriers based on cyclodextrins.Investigational new drugs · 2017Article
- Visualization of self-delivering hydrophobically modified siRNA cellular internalization.Nucleic acids research · 2017Article
- Divinyl sulfone cross-linked cyclodextrin-based polymeric materials: synthesis and applications as sorbents and encapsulating agents.Molecules (Basel, Switzerland) · 2015Article
- Methyl-β-cyclodextrin up-regulates collagen I expression in chronologically-aged skin via its anti-caveolin-1 activity.Oncotarget · 2015Article
- Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.International journal of nanomedicine · 2015Article
- Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.Critical reviews in oncogenesis · 2014Review
- Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Journal of controlled release : official journal of the Controlled Release Society · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles are being widely explored as potential therapeutics for numerous applications in medicine and have been shown to significantly improve the circulation, biodistribution, efficacy, and safety profiles of multiple classes of drugs. One leading class of nanoparticles involves the use of linear, cyclodextrin-containing polymers (CDPs). As is discussed in this paper, CDPs can incorporate therapeutic payloads into nanoparticles via covalent attachment of prodrug/drug molecules to the polymer (the basis of the Cyclosert platform) or by noncovalent inclusion of cationic CDPs to anionic, nucleic acid payloads (the basis of the RONDEL platform). For each of these two approaches, we review the relevant molecular architecture and its rationale, discuss the physicochemical and biological properties of these nanoparticles, and detail the progress of leading drug candidates for each that have achieved clinical evaluation. Finally, we look ahead to potential future directions of investigation and product candidates based upon this technology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.